Clinical trial · Interventional
Limiting Chemotherapy Side Effects by Using Moxa
Using Daily Self-administered Indirect Moxibustion to Zusanli St-36 to Reduce Chemotherapy Induced Pancytopenia: a Feasibility Study
NCT02781155CI-TRIAL-00022354unknownPhase 1 / Phase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study investigates whether it is feasible to teach cancer patients undergoing chemotherapy to self-administer daily moxibustion to reduce chemotherapy side effects. Moxibustion is a therapy used in traditional Chinese medicine that uses heat.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Neoplasms | Breast Neoplasm | ONTOLOGY_EXACT | 0.98 |
| Colorectal Neoplasms | Colorectal Neoplasm | ONTOLOGY_EXACT | 0.98 |
| Genital Neoplasms, Female | Female Reproductive System Neoplasm | ALIAS | 0.90 |
| Toxicity Due to Chemotherapy | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Moxibustion | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- Self administration of moxibustion
- description
- Participants will be taught to self administer moxibustion to the acupuncture point Zusanli St-36, and apply it daily throughout their chemotherapy treatments
- interventionNames
- Other: Moxibustion
Primary outcomes (1)
- measure
- Adherence to moxa regimen assessed by Daily Moxa Diary
- timeFrame
- 21 days after last chemotherapy cycle
- description
- The primary aim of this study is to assess the feasibility of teaching cancer patients undergoing chemotherapy in the National Health Service (NHS) to self-administer daily indirect moxibustion to St 36 Zusanli, according to a protocol that begins ideally 7 to 10 days prior to the first chemotherapy cycle and continues until 21 days after the final chemotherapy cycle. Participants will complete a Daily Moxa Diary to record their adherence to the daily protocol. They will be asked also to log any days they miss, and give reasons why.
Secondary outcomes (7)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * with breast, gynaecologic, or colorectal cancer who are prescribed radical or adjuvant chemotherapy in the early disease setting, or first or second line chemotherapy is in the metastatic setting * about to commence a course of chemotherapy for which granulocyte-colony stimulating factor (G-CSF) is not routinely indicated * with a life expectancy of more than six months * with blood cell counts within the normal range * with calculated creatinine levels of ≥ 50ml/min * English speaking * able to understand instructions for self-administration of moxibustion and carry out the procedure * able to give informed consent Exclusion Criteria: * having a haematological cancer diagnosis * prescribed a chemotherapy regimen for which G-CSF is indicated * having third or fourth line chemotherapy * having metastatic bone cancer * who have concomitant severe medical problems preventing participation * with cognitive impairment that would impact participant's ability to safely administer self-moxibustion * having renal dysfunction * with lymphedema in the lower body.
References
Publications (0)
Data not yet available
No reference posted for this study.